Farxiga (Dapagliflozin Propanediol) - Drug Interactions, Contraindications, Overdosage, etc

DRUG INTERACTIONS

Positive Urine Glucose Test

Monitoring glycemic control with urine glucose tests is not recommended in patients taking SGLT2 inhibitors as SGLT2 inhibitors increase urinary glucose excretion and will lead to positive urine glucose tests. Use alternative methods to monitor glycemic control.

Interference with 1,5-anhydroglucitol (1,5-AG) Assay

Monitoring glycemic control with 1,5-AG assay is not recommended as measurements of 1,5-AG are unreliable in assessing glycemic control in patients taking SGLT2 inhibitors. Use alternative methods to monitor glycemic control.

OVERDOSAGE

There were no reports of overdose during the clinical development program for FARXIGA.

In the event of an overdose, contact the Poison Control Center. It is also reasonable to employ supportive measures, as dictated by the patient’s clinical status. The removal of dapagliflozin by hemodialysis has not been studied.

CONTRAINDICATIONS

• •History of a serious hypersensitivity reaction to FARXIGA [see Adverse Reactions ].
• •Severe renal impairment, end-stage renal disease (ESRD), or patients on dialysis [see Use in Specific Populations ].